In another historic first for advancing research into the uses of cannabis for pharmaceutical purposes, the University of Washington (UW) has entered into a deal with Canadian-based Pascal Biosciences. Negotiated by CoMotion, UW’s incubation group, the partnership involves UW licensing a cannabinoid-based compound, ST-403 (ST) for use in various pharma products.
The research is planned to take place at the newly licensed Lumir Lab, which is located on the Hebrew University campus. According to the article, there are over 180 million women worldwide who suffer from the condition. According to Gynica, the female human reproductive organs contain the most receptors for cannabinoids,
According to a recent announcement made by Revive Therapeutics, the company has been granted an FDA Orphan Drug Designation for the use of cannabidiol (“CBD”) in preventing ischemia and reperfusion injury (“IRI”) — both of which can result from solid organ transplantation. Under the Orphan Drug Act of 1983, the FDA
In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures the